ATTOVIA THERAPEUTICS INC
ATTONASDAQ🏆 #2707 by market capUS Equity
$15.79—
Last available close · quote unavailableTrack ATTO
Get earnings, price moves & breaking news on Telegram
24h—
7d▲ 9.3%
14d▲ 6.8%
30d▼ 12.9%
ytd—
1y—
🏦Market Cap
$634M
Small Cap
📈Revenue Growth (YoY)
0.0%
Slowing
📊Gross Margin
-8.4%
Thin
💵FCF Margin
-7842.9%
Thin
⚖️P/S Ratio
1408.1x
Expensive
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- —
- 52-Week Range
- $12.94 – $28.00
- Volume (shares)
- —
- Avg Volume (shares)
- —
- Shares Outstanding
- 45.7M
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- $1M
- Last Q Revenue
- $450,000
- P/E Ratio
- -14.9
- P/S Ratio
- 1408.1x
- EPS (TTM)
- $-0.86
- Dividend Yield
- 0.00%
ATTOVIA THERAPEUTICS INC
ATTOFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1M▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$67M▲ +61.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$62M▲ +67.1% YoY
StockOtter · stockotter.spaceAbout ATTOVIA THERAPEUTICS INC
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.
Latest News & Updates
News unavailable.